Minimal Monitoring of Ovulation Induction (OI) Is It Safe? Mustafa Uğur Zekai Tahir Burak Women’s Health Education and Research Hospital, Ankara, Turkey.

Slides:



Advertisements
Similar presentations
Ovulation induction TAQI Consultant OB/GYN,Infertility,IVF
Advertisements

In Vitro Fertilization
ALTERNATE DAY TRIPTORELIN: A COST EFFECTIVE METHOD FOR CONTROLLED OVARIAN HYPERSTIMULATION E. Karatekeli, H. Özörnek, E. Ergin, B. Ongun EUROFERTIL REPRODUCTIVE.
Luteal Phase Support in ART Cycles
Ovarian Ageing and Fertility
 OHSS is a serious, potentially life- threatening, iatrogenic complication of “controlled” ovarian stimulation.  To optimize the ovarian response without.
‘President’s Medal’ for best medical graduate ‘Dr. B.C Roy’s award’ in 1999 for outstanding contribution towards medicine and field of specialty,
Shahar Kol, Maccabi Health Care Services Rambam Health Care Campus Technion, Israel Institute of Technology.
ART-IVF: the Long and Short of it Professor Ernest Hung Yu NG Department of Obstetrics & Gynaecology The University of Hong Kong.
Individualization of Cycle Control
Elonva in poor responders
LIFE AFTER NEW IVF LEGISLATION IN TURKEY Hakan Ozornek, MD EUROFERTIL Istanbul.
INDIVIDUALIZED IVF TREATMENT
The Women’s Clinic 婦產科中心 New Concept of Controlled Ovarian Stimulation in IVF Dr. Milton Leong MDCM DSc (McGill) Director, IVF Center, HKSH Specialist.
The Effect of PCOS Treatment on Ovarian Function
Role of Anti-Mullerian hormone in prediction of Assisted Reproductive Technology outcomes Leili Safdarian M.D. Khadigeh Khosravi M.D. Marzieh Agha Hosseini.
IVM is ready as a treatment for PCOS patients
Does exogenous LH activity influence the outcome in IVF and not in ICSI cycles? Peter Platteau, Johan Smitz, Carola Albano, Per Sørensen Joan-Carles Arce.
Safety and efficacy of FSH drugs in ART for polycystic ovarian disease M. Aboulghar Cairo, Egypt.
ART Assisted reproductive technology Dithawut Khrutmuang MD.
TEMPLATE DESIGN © Oocyte donation outcomes at Alpha International Fertility Centre IntroductionResultsConclusions References.
Planning of GnRH antagonist cycles
Microinjection and Fallopian Transfer (MIFT) - an effective form of Assisted Reproductive Technology(ART) for the treatment of severe male infertility.
The optimal choice of gonadotrophin in GnRH antagonist protocols Prof Dr P Devroey.
Hakan Özörnek EUROFERTIL IVF Center Turkey.  No or minimal stimulation  Low cost  Less monitoring  Less side effects (OHSS)  Acceptable pregnancy.
Dr. Milton Leong Director
The Effect of Bromocriptine-Rebound Method on Ongoing Pregnancy and Live Birth after Intracytoplasmic Sperm Injection Cycles: a Randomized Clinical Trial.
The 4th Misurata scientific meeting of infertility Benghazi – Libya 10/10/2008 Dr. Omar A. Elsraiti Consultant of Obst. & Gyn. IVF Centre - Misurata /
TEMPLATE DESIGN © IMPACT OF SEXUAL ABSTINENCE DURATION ON ICSI OUTCOME May Kew Loke and Pak Seng Wong Sunfert International.
SL ‘00 Antagonists in patients with previous poor ovarian response Antagonists in patients with previous poor ovarian response Geoffrey H Trew Consultant.
Agonist vs Antagonist Dr. Milton Leong.
How to schedule GnRH antagonist cycles?
Recommended Dosage of GnRH Antagonist is Too High Presented by Dr. Milton Leong, MD DSc(McGill) Director, IVF Centre.
Methods of assisted reproduction MUDr.Jitka Řezáčová ÚPMD, Praha 4, Podolí.
ART FOR PCOS-DIFFICULTIES AND SOLUTIONS Dr. Bulent Urman American Hospital, ISTANBUL Assisted Reproduction Unit Koç University, Faculty of Medicine Department.
Dr. Hakan Özörnek EUROFERTIL IVF Center
A review on the luteal phase P Devroey MD PhD Centre for Reproductive Medicine Dutch-speaking Brussels Free University Brussels - Belgium.
NEW STRATEGIES FOR OHSS PREVENTION Ali Rüştü Ergür, M.D., Assoc.Prof. GATA Haydarpaşa Hospital The 2nd Congress of Current Opinion in Reproductive Medicine.
Luteal coasting post GnRH agonist trigger
Clinical Trials – Human Gonadotropin Drug Products A Regulatory Perspective Shelley R. Slaughter, M.D., Ph. D. Reproductive Medical Officer Team Leader.
Is It Time To Replace Ovarian Stimulation in IVF With Alternatives
In-vitro maturation: patient selection and results Aygul Demirol Assoc Prof, Medical Director GURGAN CLINIC IVF Center, Ankara-Turkey.
(Miz Medi Hospital) Jung-Hyun Cho, M.D. (Miz Medi Hospital) Minimal Ovarian Stimulation.
IVF TROUBLESHOOTING ( Clinical Perspective) Malvin Emeraldi M. Luky, Dianing ASR,Muchsin J Family Fertility Center, RSIA Family Fatmawaty Hospital Jakarta,
Fertility Facts Definition:unprotected sex for one year, not pregnant
An analysis of 2,566 cycles Premature progesterone rise negatively correlated with live birth rate in IVF cycles with GnRH agonist: An analysis of 2,566.
The Endometrium and Frozen Embryo Transfer
Hormonal parameters used to optimize COH, Suzan tip merkezi, doc. dr. ozkan aydin leylek.
The effectiveness of gonadotropin-releasing hormone antagonist in poor ovarian responders undergoing in vitro fertilization: a systematic review and meta-analysis 
Schematic diagram of idealized regimens using exogenous gonadotropins for fertility induction. A. Step-up regimen for ovulation induction. After menses,
The timeline shows the day of menstrual cycle for a typical patient
How IVF Protocols Work to Enhance the Success of IVF: Agonist vs Antagonist Dr Dimitrios Dovas MD Newlife IVF Greece.
ultrasound of the female pelvis
Drug protocols for ovulation induction. A
Drug protocols for ovulation induction. A
Ovarian Hyper Stimulation Syndrome (OHSS)
Use of GnRH antagonists for IVF
Mohamed Elmahdy MD. Lecturer Obs. Gyn. Alexandria University Egypt
The approach to the PCOS patient undergoing IVF
به نام خدا Ovarian hyperstimulation syndrome
Reproduction-Related Disorders
Oocyte Donation; Factors Influencing The Outcome
Supplemental Table 2. Reproductive outcomes
Drug protocols for ovulation induction. A
The effect of the duration of stimulation on ART outcomes
How to do a study? Prof. P. Devroey.
The effectiveness of gonadotropin-releasing hormone antagonist in poor ovarian responders undergoing in vitro fertilization: a systematic review and meta-analysis 
Dr. Kenneth Egwuda MBBS, PGA-ART(Lon), ESGE(Belg.),FMAS,FWACS,FMCOG
Shahar Kol, IVF Unit, Elisha Hospital, Haifa, Israel
First live birth after ovarian stimulation using a chimeric long-acting human recombinant follicle-stimulating hormone (FSH) agonist (recFSH-CTP) for.
Presentation transcript:

Minimal Monitoring of Ovulation Induction (OI) Is It Safe? Mustafa Uğur Zekai Tahir Burak Women’s Health Education and Research Hospital, Ankara, Turkey

Outline Why to monitor OI in IVF? How to monitor OI in IVF? What does “minimal stimulation-monitoring” mean? What is the evidence in the literature? Which patients are (not) suitable? What is my opinion?

Milestones in OI for IVF Gonadotrophins to induce multiple follicles GnRH agonist/antagonist for premature luteinization TVUS guided OPU Hormonal assays and US for monitoring OI Simple and cheap IVF? “Patient friendly” protocols and monitoring? Do we alter outcome? Success? Complications?

Keys of success in OI Choose the optimal protocol, drug and dose Age, FSH, ovarian follicles, previous OI Assess ovarian response to OI (Monitoring) Successful completion of therapy

Why to monitor OI? Evaluate ovarian suppression (long GnRH-a protocol) Evaluate endometrial maturily Find out optimal dose of gonadotrophin Identify Hypo responders Hyper responders Avoid OHSS Reduce multiple pregnancies

How to monitor OI? Ultrasound Size and number of ovarian follicles Endometrial thickness and pattern Hormonal assays Estradiol Progesterone LH Combining US and E 2

Monitoring OI (long protocol) normoresponder -E 2 -E 2 -E 2 -E 2 -us -us -us -us E us

Monitoring OI long protocol hyper responder -E 2 -E 2 -E 2 -E 2 -E 2 -E 2 -us -us -us -us -us -us E us

Monitoring OI Antagonist Protocol -E 2 -E 2 -E 2 -E 2 -us -us -us -us E us

E 2 +US are mainstay in many IVF programmes How about LH and Progesterone?

What does “Minimal Monitoring” mean? Reduced number of US and hormonal assays? E 2 only monitoring? How many? US only monitoring? How many?

Estradiol Only Monitoring In the early days of IVF Levran et al. Fertil Steril, 1985 Wramsby et al. Human Reproduction, 1987 Today, not accepted.

Why Ultrasound Only Monitoring? Hormonal assays not available Satellite IVF induction Assays not reported on the same day To minimize the cost

Ultrasound only monitoring us us us us No E 2, P, LH 2-4 us

Can Ultrasound Only Monitoring Predict ovarian down regulation? Follicular and endometrial development? Timely administration of hCG? with No decrease in pregnancy rates No increase in OHSS

Can Ultrasound Predict Ovarian Down Regulation? 183 IVF cycles (long GnRH-a protocol) E 2 +US before ovarian stimulation E 2 >55 pg/ml when endometrium >8mm=93.3% cycles E 2 <55 pg/ml when endometrium <6mm=95.6% cycles Endometrium <6 mm predicts down regulation in over 95% of cases Barash et al, Fertil Steril 1998

Endometrial Thickness vs. Estradiol Barash et al, Fertil Steril 1998

Which Patients are Suitable for US Only Monitoring? Patients with a predicted ovarian response not poor or hyper responders Fixed dose milder stimulation CC+HMG Vlaisavljevic 1992, Kemeter 1989 HMG Golan 1995, Murad 1998 rec FSH Lass 2003, Berger 2004

Ultrasound only monitoring -Nilsson et al.J In Vitro Fert Embry Transf, 1985RE -Howard et al. J In Vitro Fert Embry Transf, 1988RE -Kemeler et al.Human Reproduction, 1989RE -Vlaisavljevic et al. Int J Gynecol Obstet, 1992 NO CONTROL -Massey et al.J. Assist Reprod Genet, 1994RE -Wikland et al.Human Reproduction, 1994RE -Roest et al.Fertil Steril, 1995RE -Golan et al.Human Reproduction, 1995PR -Murad et al.Int J. Gynecol Obslet, 1998PR -Ben-Shlomo et al.Fertil Steril, 2001RE -Hurst et al.Fertil Steril, 2002PR ANALYZE -Thomask et al.Acta Obstet Gynecol Scanol,2002RE -Lass et al.Fertil Steril, 2003PR

USG vs. USG+E 2 Long GnRH-a +HMG USG USG,E 2,LH,PP Duration OI10,911,5NS HMG ampoules34,837,9NS Oocytes retrieved11,713,4NS Embryos transferred2,62,8NS Embryos frozen1,91,3NS Pregnancy rates27,226,5NS No difference in OHSS Golan at al, Hum Reprod, 1995 n=114

USG vs. USG+E 2 Long GnRH-a +HMG USG every otherdaydaily USG+E 2 P (n:110) (n:96) Patients underwent retrieval110 87NS Oocytes retrieved NS Mature oocytes812 (75%) 735 (90%) <0,0072 Immature oocytes201 (18%) 55 (5,8%) <0,001 Fertilized oocytes711 (66%) 652 (80%) <0,001 Patients embryo transferred 81 (73%) 70 (80%) NS Clinical pregnany 19/81 (23%) 16/70 (22%)NS OHSS1 1 NS Take home baby12/81 (14%) 10/70 (14%)NS Monitorization cost 110 USD 314 USD <0,001 (hormone+US+Transport) Murad et al. Int J Gynecol Obtet, 1998

USG vs. US+E 2 Long GnRH-a+rec FSH Multicenter PR study E2/Follicle ratio (n=143) us only (n=145)P Duration OI10,2 10,1NS FSH dose NS Oocytes retrieved11,4 11,7NS Fertilized oocytes6,6 6,4NS Embryos transferred2,3 2,3NS Clinical pregnancies49 (34,3 %) 46 (31,7%)NS Lass A, UK timing of hCG Group Fertil Steril, 2003

The addition of E2/follicle criteria to ultrasound monitoring of IVF cycles in normal responders seldom changes the timing of hCG and does not increase pregnancy rates or the risk of OHSS

Pitfalls of Minimal Monitoring Not suitable for step-up, step-down protocols Dose adjustment, changing drugs, coasting not possible Follicle / E 2 discrepancy over looked Does it alter outcome?

Cost of IVF in Turkey (Turkish Medical Association 2008) OI and Monitorization280 YTL200 USD (6% of total cost) OPU1100 YTL780 USD ICSI840 YTL600 USD Embryoculture1680 YTL1200 USD Embriyotransfer840 YTL600 USD TESE840 YTL600 USD Overall IVF Cost=OI+OPU+ICSI+EC+ET4212 YTL3000 USD

Conclusion Standard monitoring of OI is with serial E 2 +US Minimal monitoring mainly refers to US only monitoring Normo responder patients can be monitored with US only with limited number of scans Minimal monitoring is not suitable for all patients and should not be “routine” of an IVF programme